Agilon Health, Inc. beat EPS estimates 31% of the time across 16 reported quarters (5 beats, 11 misses), averaging -26.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $1.04 | not reported | not reported | |
| Q1 FY26 | $1.13 | $1.80 | +59.3% | Beat | |
| Q4 FY25 | $-0.27 | $-0.46 | -70.4% | Miss | |
| Q3 FY25 | $-0.18 | $-0.27 | -50.0% | Miss | |
| Q2 FY25 | $-0.11 | $-0.25 | -127.3% | Miss | |
| Q1 FY25 | $-0.01 | $0.00 | +100.0% | Beat | |
| Q4 FY24 | $-0.22 | $-0.25 | -13.6% | Miss | |
| Q3 FY24 | not reported | $-0.29 | not reported | not reported | |
| Q2 FY24 | $-0.07 | $-0.07 | +0.0% | Beat | |
| Q1 FY24 | not reported | $0.01 | not reported | not reported | |
| Q4 FY23 | $-0.28 | $-0.41 | -46.4% | Miss | |
| Q3 FY23 | $-0.05 | $-0.06 | -20.0% | Miss |
Back to AGL overview · AGL holders · AGL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.